Erratum 1: Centrally administered adrenomedullin 5 activates oxytocin-secreting neurons in the hypothalamus and elevates plasma oxytocin level in rats

in Journal of Endocrinology
Authors:
H Otsubo
Search for other papers by H Otsubo in
Current site
Google Scholar
PubMed Close
,
S Hyodo
Search for other papers by S Hyodo in
Current site
Google Scholar
PubMed Close
,
H Hashimoto
Search for other papers by H Hashimoto in
Current site
Google Scholar
PubMed Close
,
M Kawasaki
Search for other papers by M Kawasaki in
Current site
Google Scholar
PubMed Close
,
H Suzuki
Search for other papers by H Suzuki in
Current site
Google Scholar
PubMed Close
,
T Saito
Search for other papers by T Saito in
Current site
Google Scholar
PubMed Close
,
T Ohbuchi
Search for other papers by T Ohbuchi in
Current site
Google Scholar
PubMed Close
,
T Yokoyama
Search for other papers by T Yokoyama in
Current site
Google Scholar
PubMed Close
,
H Fujihara
Search for other papers by H Fujihara in
Current site
Google Scholar
PubMed Close
,
T Matsumoto
Search for other papers by T Matsumoto in
Current site
Google Scholar
PubMed Close
,
Y Takei
Search for other papers by Y Takei in
Current site
Google Scholar
PubMed Close
, and
Y Ueta
Search for other papers by Y Ueta in
Current site
Google Scholar
PubMed Close
DOI:
https://doi.org/10.1677/JOE-09-0009e
Volume/Issue:
Volume 202: Issue 3
Article Type:
Addendum
Page Range:
483
Online Publication Date:
Sep 2009
Copyright:
© 2009 Society for Endocrinology 2009
A RELATED ARTICLE IS AVAILABLE
Free access

Sign up for journal news

The authors and the journal apologise for errors that have occurred in this paper published in 2009 202 237–247.

The following sentence in the abstract should read as

This induction was significantly but not completely reduced by pre-treatment with both the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8–37) (3 nmol/rat) and the AM receptor antagonist AM-(22–52) (27 nmol/rat).

and not as published.

Further the keys to panel D of Figs 4 and 5 were also wrong. The correct figures are published in full below:

Figure 4
Figure 4

Topographical mapping of Fos-LI and OXT-LI or AVP-LI in the SON 90 min after i.c.v. administration of vehicle (A and C) or AM5 (2 nmol/rat: B and D). (A and B) Coexistence of Fos-LI and OXT-LI (▴). (C and D) Coexistence of Fos-LI and AVP-LI (▪). •, Fos-LI-positive cells; Δ, OXT-LI-positive cells; □, AVP-LI-positive cells. In each panel, two 30-μm thick coronal sections from the SON were selected. Bar indicates 50 μm.

Citation: Journal of Endocrinology 202, 3; 10.1677/JOE-09-0009e

Figure 5
Figure 5

Topographical mapping of Fos-LI and OXT-LI or AVP-LI in the PVN 90 min after i.c.v. administration of vehicle (A and C) or AM5 (2 nmol/rat: B and D). (A and B) Coexistence of Fos-LI and OXT-LI (▴). (C and D) Coexistence of Fos-LI and AVP-LI (▪). •, Fos-LI-positive cells; Δ, OXT-LI-positive cells; □, AVP-LI-positive cells. In each panel, two 30-μm thick coronal sections from the PVN were selected. Bar indicates 50 μm.

Citation: Journal of Endocrinology 202, 3; 10.1677/JOE-09-0009e

Journal of Endocrinology is committed to supporting researchers in demonstrating the impact of their articles published in the journal.

The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.

More information is on the Reasons to publish page.

Sept 2018 onwards Past Year Past 30 Days
Full Text Views 254 68 30
PDF Downloads 58 21 6

 

  • Collapse
  • Expand
Print ISSN:
0022-0795
Online ISSN:
1479-6805
Copyright:
© 2009 Society for Endocrinology 2009
Page(s):
1
Article Type:
Addendum
Print Publication Date:
01 Sep 2009
Online Publication Date:
Sep 2009
  • View in gallery

    Topographical mapping of Fos-LI and OXT-LI or AVP-LI in the SON 90 min after i.c.v. administration of vehicle (A and C) or AM5 (2 nmol/rat: B and D). (A and B) Coexistence of Fos-LI and OXT-LI (▴). (C and D) Coexistence of Fos-LI and AVP-LI (▪). •, Fos-LI-positive cells; Δ, OXT-LI-positive cells; □, AVP-LI-positive cells. In each panel, two 30-μm thick coronal sections from the SON were selected. Bar indicates 50 μm.

  • View in gallery

    Topographical mapping of Fos-LI and OXT-LI or AVP-LI in the PVN 90 min after i.c.v. administration of vehicle (A and C) or AM5 (2 nmol/rat: B and D). (A and B) Coexistence of Fos-LI and OXT-LI (▴). (C and D) Coexistence of Fos-LI and AVP-LI (▪). •, Fos-LI-positive cells; Δ, OXT-LI-positive cells; □, AVP-LI-positive cells. In each panel, two 30-μm thick coronal sections from the PVN were selected. Bar indicates 50 μm.

Topographical mapping of Fos-LI and OXT-LI or AVP-LI in the SON 90 min after i.c.v. administration of vehicle (A and C) or AM5 (2 nmol/rat: B and D). (A and B) Coexistence of Fos-LI and OXT-LI (▴). (C and D) Coexistence of Fos-LI and AVP-LI (▪). •, Fos-LI-positive cells; Δ, OXT-LI-positive cells; □, AVP-LI-positive cells. In each panel, two 30-μm thick coronal sections from the SON were selected. Bar indicates 50 μm.

Topographical mapping of Fos-LI and OXT-LI or AVP-LI in the PVN 90 min after i.c.v. administration of vehicle (A and C) or AM5 (2 nmol/rat: B and D). (A and B) Coexistence of Fos-LI and OXT-LI (▴). (C and D) Coexistence of Fos-LI and AVP-LI (▪). •, Fos-LI-positive cells; Δ, OXT-LI-positive cells; □, AVP-LI-positive cells. In each panel, two 30-μm thick coronal sections from the PVN were selected. Bar indicates 50 μm.